AI in Healthcare Must Be Guided by Ethics and Equity, Says Nadda

IMT News Desk
IMT News Desk
· 2 min read
AI in healthcare must be guided by ethical oversight, strong regulation and equity, JP Nadda tells WHO members at the 79th World Health Assembly, Geneva

Artificial intelligence can transform healthcare but must be governed by strong ethics, robust regulation and an unwavering focus on equity to truly serve people, Union Health Minister J P Nadda has said. Addressing a side event on “Artificial Intelligence in Health: Laws, Ethical Oversight, Research and Equity” at the 79th World Health Assembly in Geneva, he warned that AI could either bridge healthcare gaps or deepen inequities depending on how it is designed, deployed and regulated.

Nadda underlined that India is building its AI journey on the foundations of the Ayushman Bharat Digital Mission and a trusted, interoperable health data ecosystem to ensure patient safety, accountability and transparency. He highlighted the Strategy for AI in Healthcare for India (SAHI), launched earlier this year, describing it as a comprehensive, people-centric framework from the Global South to steer AI innovation ethically and transparently.

To operationalise safe and inclusive AI, the minister pointed to BODH, the Benchmarking Open Data Platform for Health AI, which evaluates AI tools against real-world datasets to check their performance across India’s diverse population and settings. He stressed that digitisation and data alone are not enough to improve health outcomes, and called for rigorous research, clinical validation and continuous oversight before AI solutions are scaled in clinical practice.

Calling for global cooperation, Nadda said no country can manage AI’s risks and opportunities in isolation and urged partnerships to strengthen governance norms, research collaborations and ethical standards worldwide. “Innovation must be guided by regulation, scale must be earned through trust, and technological advancement must remain anchored in equity, ethics and public good,” he said, adding that the future of AI in healthcare will be determined more by collective human choices than by algorithms themselves.

Read Next

India’s first focused health AI Conclave unites doctors and AI experts
Featured Article
July 10, 2026

India’s first focused health AI Conclave unites doctors and AI experts

• Global Healthcare Academy hosts HAI Conclave 2026, India’s first national platform dedicated to Healthcare and Artificial Intelligence • Landmark Bengaluru conference brings together healthcare leaders and AI experts to explore how Artificial Intelligence can make healthcare faster, safer and more accessible while keeping patients at the centre of every decision The inaugural edition of the HAI Conclave […]
Article by: IMT News Desk
Fischer Medical Ventures Highlights NYB.AI Partnership as Platform Showcased at NVIDIA GTC Taiwan 2026
News
July 10, 2026

Fischer Medical Ventures Highlights NYB.AI Partnership as Platform Showcased at NVIDIA GTC Taiwan 2026

Fischer Medical Ventures Limited (FMVL) has announced that its strategic partner, Nanyang Biologics, has achieved a major international milestone with its AI-powered molecular research platform, NYB.AI, being featured in the opening showcase at NVIDIA GTC Taiwan 2026, ahead of the keynote address by NVIDIA Founder and CEO Jensen Huang. The recognition places NYB.AI among a […]
Article by: IMT News Desk
Pharma Q1 Margins Seen Under Pressure Despite Revenue Growth: Goldman Sachs
News
July 10, 2026

Pharma Q1 Margins Seen Under Pressure Despite Revenue Growth: Goldman Sachs

Indian pharmaceutical companies are expected to report healthy revenue growth in the first quarter of FY27, but margins are likely to compress as sector profitability comes under pressure. In a recent preview note, Goldman Sachs said it anticipates around 185 basis points year-on-year margin decline for the sector in the June quarter, driven primarily by […]
Article by: IMT News Desk
Dr Reddy’s Delays Semaglutide Supplies After Active Ingredient Quality Issue
News
July 10, 2026

Dr Reddy’s Delays Semaglutide Supplies After Active Ingredient Quality Issue

Dr Reddy’s Laboratories has announced a delay in commercial supplies of its semaglutide product after certain batches were found to be out of specification due to an issue with the active pharmaceutical ingredient (API) used in the drug. The company said it has initiated an investigation into the root cause and is taking corrective measures […]
Article by: IMT News Desk